Leading vascular biologists from Yale, Harvard, Uppsala and the University of Eastern Finland join Sessa to advise on the development of ISM-001,

来自耶鲁大学、哈佛大学、乌普萨拉大学和东芬兰大学的顶尖血管生物学家加入Sessa的团队，为ISM-001的开发提供指导，

Isomab's

Isomab的

first-in-class anti-VEGF-A165b antibody for chronic angina

用于慢性心绞痛的首创抗VEGF-A165b抗体

CAMBRIDGE, England

英国剑桥

,

，

Sept. 29, 2026

2026年9月29日

/PRNewswire/ -- Isomab Ltd ('Isomab') a UK-based biotechnology company developing novel therapies to restore vascularization in cardiovascular disease, today announced the appointment of Professor Bill Sessa, PhD, former Chief Scientific Officer of Internal Medicine at Pfizer and the Alfred Gilman Emeritus Professor of Pharmacology at Yale School of Medicine, as Chair of its Scientific Advisory Board (SAB)..

/美通社/ -- 英国生物技术公司 Isomab Ltd（“Isomab”）致力于开发恢复心血管疾病血管化的新型疗法，今日宣布任命比尔·塞萨教授（Bill Sessa，博士）为其科学顾问委员会（SAB）主席。塞萨教授曾任辉瑞公司内部医学首席科学官，以及耶鲁大学医学院阿尔弗雷德·吉尔曼药理学荣休教授。

Continue Reading

继续阅读

Isomab

异马布

Professor Sessa will lead an SAB comprising internationally recognised experts in vascular biology from Yale, Harvard Medical School, Uppsala University and the University of Eastern Finland, alongside Isomab Co-founder and Chief Scientific Offic

塞萨教授将领导一个科学顾问委员会，该委员会由来自耶鲁大学、哈佛医学院、乌普萨拉大学和东芬兰大学的国际公认血管生物学专家，以及Isomab公司联合创始人兼首席科学官组成。

er, Pro

呃，Pro

fessor David Bates.

大卫·贝茨教授。

The appointment comes as Isomab advances ISM-001 (vexobicizumab), its first-in-class anti-VEGF-A165b monoclonal antibody, toward first-in-human dosing for chronic angina refractory to standard-of-care treatment. The Company is completing a key clinical biomarker study and strengthening its preclinical package ahead of clinical development..

此次任命之际，Isomab 正推进其首创的抗 VEGF-A165b 单克隆抗体 ISM-001（vexobicizumab）向首次人体给药阶段迈进，该药物旨在治疗对标准疗法难治的慢性心绞痛。公司正在完成一项关键的临床生物标志物研究，并在临床开发前加强其临床前研究资料包。

'VEGF-A165b antagonism represents a genuinely novel approach to restoring vascularization in ischaemic disease,' said Professor Bill Sessa. 'I have spent much of my career studying the molecular biology of eNOS and the vascular endothelium, and I am excited to help guide

“VEGF-A165b拮抗作用代表了一种真正新颖的恢复缺血性疾病血管化的方法，”Bill Sessa教授表示。“我职业生涯的大部分时间都致力于研究eNOS和血管内皮的分子生物学，我很高兴能够协助指导

Isomab's team

伊索马布团队

as they translate two decades of foundational science into a potential therapy for patients with chronic angina, a condition where treatment options remain limited.'

在他们将二十年的基础科学研究转化为慢性心绞痛患者潜在疗法的过程中，这种病症的治疗选择仍然有限。

'This is an exceptional group of scientists whose collective work has defined much of what we know about vascular biology today,' said Philip Brainin, MD, PhD, MBA, Chief Executive Officer of Isomab. 'As we advance ISM-001 toward the clinic, having Bill and this board rigorously challenge our mechanistic narrative and preclinical package, while helping us determine where the 165b biology could take us next, is an enormous asset to the Company and, ultimately, to patients with cardiovascular disease.'.

“这是一支杰出的科学家团队，他们的集体工作奠定了当今我们对血管生物学的大部分认知，”Isomab公司首席执行官Philip Brainin医学博士、哲学博士、工商管理硕士表示。“在我们推动ISM-001迈向临床应用的过程中，Bill及董事会成员对我们的作用机制叙述和临床前研究方案进行严格审视，同时帮助我们明确165b生物学研究的未来方向，这对公司乃至最终对心血管疾病患者而言，都是一笔巨大的财富。”

Joining Professor Sessa on the SAB are:

加入科学顾问委员会（SAB）的塞萨教授还有：

Professor Tim Hla, Patricia K. Donahoe Professor of Surgery at Boston Children's Hospital and Harvard Medical School, known for his discovery of the COX-2 pathway and the first S1P receptor.

蒂姆·赫拉教授，波士顿儿童医院和哈佛医学院的帕特里夏·K·多纳霍外科学教授，以发现COX-2通路和首个S1P受体而闻名。

Professor Lena Claesson-Welsh, Professor in the Department of Vascular Biology at Uppsala University and an internationally recognised authority on VEGFR2 signal transduction.

乌普萨拉大学血管生物学系教授Lena Claesson-Welsh，是国际公认的VEGFR2信号转导领域权威。

Professor Seppo Ylä-Herttuala, Professor at the Institute for Molecular Sciences at the University of Eastern Finland and a pioneer of cardiovascular gene therapy and the application of adenoviral gene transfer in cardiovascular disease.

塞波·伊拉-赫图阿拉教授，芬兰东大学分子科学研究所教授，心血管基因疗法及腺病毒基因转移在心血管疾病中应用的先驱。

Professor David Bates, Co-founder and Chief Scientific Officer of Isomab and Professor at the University of Nottingham, whose more than two decades of research underpin Isomab's VEGF-A165b science.

大卫·贝茨教授，Isomab联合创始人兼首席科学官，诺丁汉大学教授，其二十余年的研究成果为Isomab的VEGF-A165b科学奠定了坚实基础。

About

关于

Isomab

伊索单抗

Isomab Ltd is a UK-based biotechnology company developing novel antibody therapies designed to restore vascularization in cardiovascular disease. Its lead programme, ISM-001, is initially being developed for chronic stable angina refractory to standard-of-care treatment, with potential applications in peripheral arterial disease and other ischaemic conditions..

Isomab Ltd 是一家总部位于英国的生物技术公司，致力于开发新型抗体疗法，旨在恢复心血管疾病中的血管化。其核心项目 ISM-001 最初针对对标准治疗无效的慢性稳定型心绞痛进行开发，并有望应用于外周动脉疾病及其他缺血性疾病。

For more information, visit

欲了解更多信息，请访问

www.isomab.bio

www.isomab.bio

.

。

SOURCE Isomab

来源：Isomab

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示